Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Improving quality of oncology (onc) documentation and enhancing structured data collection using a standardized onc note template.
Folstad, Matthew, Augustine, Arun, Hollnagel, Fauzia, Carroll, Cibele Barbosa , Saner, Ashleigh, Pier, Jeff, Lavitschke, Michael D., Kleinschmidt, Peter , Twedt, Heidi , Tevaarwerk, Amyé , Emamekhoo, Hamid

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11128-11128

10.1200/jco.2024.42.16_suppl.11128 Get It

11128 Background: To improve documentation quality in Medical Onc outpatient clinics, a standardized template was created. In this template we embedded: 1. An Epic SmartForm to collect structured data (SD) about patient, disease, and response status at each encounter. Minimal Common Oncology Data Elements (mCODE) compatible SD elements were used to enhance interoperability. 2. Several clinically impactful quality metrics (QM) selected based on the Quality Onc Practice Initiative (QOPI) guidelines. In this analysis, we aim to assess how template use impacted documentation quality. Methods: 113,376 outpatient encounters occurred between 01/2018 – 12/2022 (41 providers: 35 physicians, 6 APPs). The template go live was 3/19/2019. 2,520 randomly selected encounters were manually reviewed. Distinct documentation of 8 items served as QMs (Table). Of note, using the template was voluntary and data entry in the embedded form is not mandated. Documentation of each QM was compared between notes authored with/without template. For each note, a completeness score was calculated based on total number of QMs present/note. Categorical comparisons were made using chi-squared or Fisher’s exact tests. Numerical/continuous values were summarized using means and standard deviations. A template “user” was defined as a provider using the template in >10% of encounters after go live. This QI project was exempted by IRB. Results: 154/2520 encounters were excluded after manual review (visits not for solid tumor malignancy). The template was used in 38.7% (917/2366) of the reviewed notes. Cancer diagnosis was documented in >99.8% of notes regardless of template use. Template use was associated with increased documentation of 7 QMs (Table). Documentation overall completeness improved from 62% to 90% with a very large effect size (Table). Template use positively correlated with female gender and fewer years since last training (p<0.001). In the subgroup of notes written by “users” (21 physicians, 4 APPs), individual QM and overall completeness scores improved with template use (p<0.001). Conclusions: Template use profoundly improved QM documentation (statistically significant and clinically meaningful) by Onc clinic providers. This strategy enhances mCODE compatible structured data collection and semantic interoperability between systems, strengthening the available real-world data (RWD) in EHR. [Table: see text]
Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.
Bakow, Brianna R. , Fan, Elaine, Ganta, Teja , Glover, Michael , Hadfield, Matthew J. , Kothari, Shalin , Sethi, Tarsheen , Singhi, Eric K. , Rubinstein, Sam , Warner, Jeremy L. , Brown, Alaina J. , Choe, Jennifer H , Fan, Elaine Y. L., Hilton, Cameron Beau , Khaki, Ali Raza , Lythgoe, Mark, Nagpal, Seema , Nguyen, Ryan H. , Noyd, David H. , Riaz, Irbaz Bin , Rooney, Michael Kevin

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11079-11079

10.1200/jco.2024.42.16_suppl.11079 Get It

11079 Background: Phase 3 randomized clinical trials (RCTs) inform the standard of care in cancer treatment yet have a mixed track record of success. In this study, we sought to 1) determine the overall success rate of phase 3 RCTs; 2) assess whether authorship patterns differ between successful (positive) and unsuccessful (negative) trials; and 3) explore if individual authors have distinct track records of success. Methods: The HemOnc knowledgebase (KB) was queried for initial publications of phase 3 RCTs of systemic anticancer therapy; those without primary outcome described were excluded. RCTs were labeled positive if the primary endpoint was met per HemOnc standard criteria (P value ≤ 0.05 or hazard ratio upper bound ≤ 1 for any experimental arm[s]) and negative if they did not meet these criteria or if the experimental arm was statistically inferior. Trial metadata and author information were extracted from the HemOnc KB. Author positive publication rate (PPR) was defined as % of publications reporting a positive result divided by total number of eligible publications. Prolific authors were defined as those with 6+ eligible publications. Author count for manuscripts reporting positive vs negative results was evaluated with the Mann-Whitney U test; other statistics were descriptive. Results: 3328 studies met criteria as of February 5, 2024; these were associated with 3305 initial publications between 1960-2023, involving 25,412 unique authors. 1474 (44.3%) of the studies were positive. Publications reporting positive trial results had, on average, 3 more authors, median (interquartile range) of 18 (12-23) vs 15 (11-20), p<0.0001. The mean (±SD) PPR for n=1967 prolific authors was 47.7% (±22.3%). The PPR was not related to individual author output; mean PPR for non-prolific authors was 48.0% (SD not reported). Differences in PPR were apparent by the disease under study and the years of publication (Table). Among the 46 prolific authors who had a PPR 2+ SD above the mean, 26 (55%) were from China followed by Italy with 3 (6%). Conclusions: Despite known positive publication bias, the success rate of published phase 3 RCTs remains <50%. Publications reporting positive results had significantly more authors; this finding requires further study including adjustment for trial sample size. Significant variation in PPR amongst fields could be due to watershed therapeutic advances, differential selection of primary endpoints, and/or selective reporting of results. Finally, a signal for geographic association of outlier PPRs suggests the need for further investigation. [Table: see text]
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.
Gage, Samantha, Eteshola, Elias , Hadfield, Matthew J. , Hamze, Dany, Masse, Gabrielle, Jain, Sandeep Kumar , Rubinstein, Sam , Khaki, Ali Raza , Mishra, Sanjay , Rooney, Michael Kevin , Hilal, Talal , Lythgoe, Mark, Warner, Jeremy L.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11030-11030

10.1200/jco.2024.42.16_suppl.11030 Get It

11030 Background: Drug regulators operate on their own timelines to assess the safety and efficacy of new drugs and/or extensions to existing indications, such that there are delays between regulators. During such a gap, patients in the “early” domain have access to the approved drug, while those in the “late” domain do not, outside of compassionate use. Our study aimed to quantify the “opportunity lost” for new therapies approved by FDA and EMA, assuming patients in the late domain receive standard-of-care (SOC) therapy – which is presumably inferior to the new drug – during the gap. Methods: Anticancer drugs approved by both FDA and EMA were identified through the HemOnc knowledgebase. Inclusion criteria included: 1) drugs approved in both domains based on the same randomized clinical trial (RCTs) for the same indication; 2) a primary time-to-event endpoint; and 3) a quantitated median time-to-event for the primary endpoint. For each included trial, the approval gap between FDA and EMA in days and the ratio of approval gap to median control arm time-to-event duration was calculated. A ratio ≥2 implies that, on average, no late domain patients starting treatment in the first half of the gap would be expected to have access to the new drug prior to an event. Results: Of 60 eligible RCTs, 59 had calculable median event durations. 25 (42%) had a primary overall survival endpoint; the most common surrogate endpoint was progression-free survival (PFS; 29/59; 49%). The median (interquartile range [IQR]) approval gap was 186 (124-271) days, with FDA being the first approver in 56/59 (95%) cases. The median (IQR) ratio of approval gap to median control arm event duration was 0.63 (0.35-1.11). Drugs with ratio ≥2 (Table) were targeted or immunotherapies; 7/8 (88%) were approved with PFS endpoint; 5/8 (62.5%) were approved for second line or later. Conclusions: Our study shows that FDA approves most drugs prior to EMA and a nontrivial number of patients may experience progression or death events while awaiting access to anticancer therapies already approved in another domain. The analysis does not take into consideration scenarios in which the new therapy is inferior to SOC or delays in patient access (due to slow uptake; regulatory barriers [in Europe/UK]; or patient affordability [in US]). Further regulatory collaboration (e.g., Project Orbis) between FDA and EMA could help to reduce and potentially ameliorate this differential in access to new cancer drugs in the future. [Table: see text]
Evaluation of the study of control arms in randomized clinical trials of cancer.
Jain, Sandeep Kumar , Sethi, Tarsheen , Rubinstein, Sam , Madireddy, Sathwik , Kulkarni, Amit , Kothari, Shalin , Hadfield, Matthew J. , Ganta, Teja , Zauderer, Marjorie G. , Schoen, Martin W. , Nguyen, Ryan H. , Nagpal, Seema , Mohan, Sanjay , Lythgoe, Mark, Liang, Wayne H. , Hilal, Talal , Goyal, Gaurav , Dholaria, Bhagirathbhai , Brown, Alaina J. , Warner, Jeremy L.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11023-11023

10.1200/jco.2024.42.16_suppl.11023 Get It

11023 Background: Randomized clinical trials (RCTs) in cancer typically compare experimental to control arm regimens. The choice of an appropriate control (ctrl) arm can have a major impact on the expected success of an RCT. The frequency with which cancer RCTs use control arms based on established dosing and scheduling protocols has not been described. Methods: The HemOnc knowledgebase (KB) was used to identify systemic anti-cancer therapy (SACT) regimen variants, defined as regimens with identical components that differ in dosing, scheduling, and/or route. Non-cancer, nonrandomized, and non-SACT studies were excluded. Study publication year was used to define standard variants as those evaluated in the experimental arm of a positive phase 3 RCT >1 year prior to publication as a control arm, regardless of cancer type or context of treatment. Study-variant dyads were evaluated to determine whether the variant was standard. Success rates of RCTs with standard vs non-standard control arms were evaluated with Fisher’s exact test. Results: 5221 studies were associated with ≥1 named variant in the HemOnc KB, as of 2024-02-06. After exclusions, there were 3511 study-variant dyads (2386 studies; 1714 variants). The 9 most common regimens are shown in the Table. The median (IQR) number of variants per regimen was 2 (1-3); carboplatin & paclitaxel (CP) had the most variants (n=33). Across all control arm study-variant dyads, 2228/3492 (64%) utilized non-standard variants. For example, 60/97 studies (62%) of docetaxel as control used the 75 mg/m2 q3wk variant after it was established in 2000, whereas n=27 others used 19 non-standard variants. Trials that used a standard control arm had a numerically higher success rate, 45% vs 42% (OR 1.10, 95% CI 0.92-1.32). Conclusions: Non-standard regimen variants are frequently used in cancer RCTs. Reasons for this could include toxicity, patient convenience, or emerging data from smaller studies that establish comparable efficacy or improved toxicity to standard variants. However, the a priori efficacy of non-standard control arms is less rigorously established, and trials with standard control arms might be more successful. Future directions include quantifying the granular differences between standard and non-standard variants and investigating whether certain types of non-standard variation (e.g. fewer cycles, lower doses) associate with trial success rates. [Table: see text]
Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic experience.
Hoppenworth, Jenna, Premji, Sarah , Smith, Deanne, Taraba, Jodi L. , Hobday, Timothy J. , Peethambaram, Prema P. , Carroll, Jamie M. , Ruddy, Kathryn J. , O’Sullivan, Ciara C. , Choong, Grace M. , Ellsworth, L., Rao, Rohit , Egan, Ashley, Haddad, Tufia C. , Leon‐Ferre, Roberto A. , Taraba, Jodi L , Tevaarwerk, Amyé , Cathcart-Rake, Elizabeth , Yadav, Siddhartha , Rao, Rohit, Goetz, Matthew P. , Giridhar, Karthik V.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11145-11145

10.1200/jco.2024.42.16_suppl.11145 Get It

11145 Background: T-DXd is increasingly used in mBC. A T-DXd toxicity of special interest is interstitial lung disease/pneumonitis (ILD), occurring in 10-15% of pts in the DESTINY-Breast trials, and with potential lower incidence/severity in earlier line settings [Krop et al, ASCO 2023]. However, in routine practice, T-DXd may be used in pts with more heavily pre-treated mBC and previously exposed to other antibody-drug conjugates (ADC) [Premji et al SABCS 2023]. We evaluated the incidence/severity of T-DXd related ILD in mBC at Mayo Clinic. Methods: We retrospectively identified pts with mBC who received ≥1 dose of T-DXd at Mayo Clinic, Rochester, MN, between July 2022-December 2023. Demographic, mBC, and pulmonary clinical variables were abstracted from the clinical records. Data was summarized using descriptive statistics. Diagnosis of ILD was determined by treating clinicians, and severity to CTCAE V5 based on clinical documentation. Results: 77 pts with mBC received T-DXd during the study period. All were female, the majority (70, 91%) were Caucasian, and median age was 58. 53 (69%) had HER2-low mBC (37 HR+, 16 HR-) and 24 (31%) had HER2+ mBC (17 HR+, 7 HR-). 31 (40%) were active or former smokers. 11 (14%) had pulmonary comorbidities, including 6 (7.8%) with asthma, 2 (2.6%) with prior pneumonitis, and 3 (3.9%) with other pulmonary comorbidities. They had previously received a median of 1 line of endocrine therapy, and 4 lines of chemotherapy, with 20 (26%) having received another ADC. 17 (22%) developed any grade ILD [G1: 3 (4%), G2: 7 (9%), G3: 2 (3%), G4: 1 (1%), G5: 4 (5%)]. Among pts with ILD of any grade, 13 (76.5%) presented with at least 1 symptom (cough/SOB). The median number of T-DXd cycles prior to onset of any grade ILD was 6 (range 2-13), or 18 (range 6-39) weeks. 5 (29%) pts with any grade ILD received a prior ADC. Of pts with ≥G3 ILD (n=7), all were Caucasian, 2 (30%) were prior smokers, none had prior lung disease, and had received a median of 5 prior lines of chemo, with 4 (57%) having received a prior ADC. All grade ≥2 ILDs were treated with systemic steroids, and 1 also received IVIG. CT chest was used for diagnosis of all ILD. 7 pts (41%) required hospitalization, all of whom had bronchoscopy, with 5 (29%) requiring intubation. All pts with G1 ILD (3, 18%) restarted T-DXd without ILD recurrence. Conclusions: In this case series,22% of ps treated with T-DXd experienced ILD (5% G5), higher than the rate observed in the pivotal DESTINY-Breast trials, possibly due to real-world use of T-DXd in more heavily pre-treated pts and in pts with pulmonary comorbidities.
Examining Changes in Shoulder Strength, Lower Body Power, and Body Composition among Collegiate Baseball Players after Completion of a Summer Baseball League Season
Merfeld, Brandon , Rowley, Matthew , Luedke, Joel, Erickson, Jacob L. , Jones, Margaret T. , Fields, Jennifer B. , Szymanski, Elijah, Jagim, Andrew R. , Jones, Margaret T , Jagim, Andrew R , Rowley, Matthew, Almonroeder, Thomas Gus

Mayo Clinic

Journal of Functional Morphology and Kinesiology | June 3, 2024 | Volume: 9 | Issue: 2 | Pages: 98

10.3390/jfmk9020098 | PMID 38921634 Get It

The strength of the shoulder musculature involved with internal rotation and arm extension plays an important role in the overhead throwing motion for baseball athletes, both for throwing-related performance and injury risk. The maintenance of shoulder strength is a high priority for baseball athletes throughout a season; however, little is known in regards to the expected changes in strength throughout a season. To examine pre-post changes in shoulder strength, lower body power, and body composition among collegiate baseball players after the completion of a summer baseball league season. Amateur baseball players (n = 12; age: 20.9 ± 1.0 years.; height: 181.6 ± 5.6 cm; body mass: 86.4 ± 11.1 kg; BMI: 26.0 ± 2.6 kg/m2) participated in the current study. Pre- and post-competitive season, the participants completed shoulder strength assessments and body composition and countermovement vertical jump (CMJ) tests. An upper-body isometric test (athletic shoulder [ASH] test) was used to evaluate shoulder strength for each arm. Each subject completed maximal isometric contractions for both the throwing and non-throwing arms at four separate angles of abduction (180°, ‘I’; 135°, ‘Y’; 90°, ‘T’; and −180°, ‘A’) while lying in a prone position. For shoulder strength, the primary dependent variable of interest was a composite measure that represented the average of the forces produced across all four positions of the ASH test (I, Y, T, A). For the ASH test composite measure, there was a trend toward a significant arm-by-time interaction effect (p = 0.08), as shoulder strength decreased by 9.03% for the throwing arm (ES = 0.72; 95% CI = [−0.27, −0.01]), compared to only 2.03% for the non-throwing arm (ES = 0.15; 95% CI = [−0.16, 0.09]), over the course of the season. The main effects of time (p = 0.16) and arm (p = 0.58) were not significant for the ASH test composite measure. There was no relationship between lower body power and throwing arm strength at baseline (r = 0.20, p = 0.56), and only a non-significant weak relationship at post-test (r = 0.28, p = 0.41). Throughout a season, baseball players may experience reductions in shoulder strength of the throwing arm with minimal changes in shoulder strength in the non-throwing arm.
Evaluation of major adverse events of clozapine based on accordance to an international titration guideline
Nuebel, Matthew , Leung, Jonathan G. , Hughes, Christopher , McGrane, Ian R. , McGrane, Ian , Leung, Jonathan G , Hughes, Christopher

Mayo Clinic

Mental Health Clinician | June 3, 2024 | Volume: 14 | Issue: 3 | Pages: 204-211

10.9740/mhc.2024.06.204 | PMID 38835819 Get It

Introduction Clozapine is the only antipsychotic approved for treatment-resistant schizophrenia, but without appropriate monitoring, it can be associated with potentially fatal outcomes. An International Adult Clozapine Titration Guideline categorizes patients into normal or slow metabolizers. Categorization provides clozapine titration schedules and recommends regular c-reactive protein (CRP) and clozapine concentration monitoring to reduce the risk of adverse drug reactions (ADRs). The impact of the guideline on clozapine ADRs has not been evaluated. Methods A retrospective chart review assessed clozapine titrations, laboratory monitoring, ADRs, and discontinuations for clozapine-naive adult inpatients at a single center from January 1, 2013, to June 1, 2022. Each patient’s cumulative weekly clozapine dosage was compared with their guideline recommended dosage to create a percent accordance. Linear logistic regression evaluated the relationship between titration speed and the presence of an ADR, while descriptive statistics analyzed laboratory monitoring. Results Forty-three patients were included, with the majority being White males with schizophrenia. An inverse relationship existed between the last inpatient week clozapine dose percent accordance and the probability of an ADR. Nonobese patients were less likely than obese patients to experience an ADR (odds ratio = 0.17; 95% CI, 0.03-0.99). CRP and clozapine concentration monitoring was suboptimal. Discussion Based on our small retrospective review of primarily White males, more aggressive clozapine titrations did not increase ADRs. Future studies with more diverse samples are needed and should focus on specific ADRs, which may have increased occurrence with rapid titrations. Obese patients were at higher risk of ADRs, correlating with the guideline-recommended slower titrations for these patients.
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole
Chapman, Judith‐Anne W. , Bayani, Jane , Sengupta, Sandip , Bartlett, John M.S. , Quintayo, Mary Anne , Virk, Shakeel , Goss, Paul E., Ingle, James N. , Ellis, Matthew J. , Budd, G. Thomas , Ansari, Rafat , Tozer, Richard , D’Souza, David , Chalchal, Haji , Spadafora, Silvana , Stearns, Vered , Perez, Edith A. , Whelan, Timothy J., Elliott, Catherine, Shepherd, Lois E. , Taylor, Karen J. , Whelan, Timothy J. , Ingle, J , Virk, Shakeel , Ellis, Matthew J , Sledge, George W , Budd, G Thomas , Rabaglio-Poretti, Manuela , Stearns, Vered , Perez, Edith A , Gelmon, Karen A , Whelan, Timothy J , Shepherd, LE , Chen, Bingshu E , Taylor, Karen J , Piper, Tammy , Sledge, George W. , Rabaglio, Manuela , Gelmon, Karen A. , Chen, Bingshu E. , Whelan, Timothy J

Mayo Clinic

Journal of Clinical Oncology | June 2, 2024 | Volume: 42 | Issue: 24 | Pages: 2887-2898

10.1200/jco.24.00835 | PMID 38824432 Get It

PURPOSE ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity with breast cancer outcomes. METHODS MA.27 (ClinicalTrials.gov identifier: NCT00066573 ) was a phase III adjuvant trial of exemestane versus anastrozole in postmenopausal women with early-stage breast cancer. Immunochemistry ER and PgR HSCORE and % positivity (%+) were centrally assessed by machine image quantitation and statistically standardized to mean 0 and standard deviation (SD) 1 after Box-Cox variance stabilization transformations of square for ER; for PgR, (1) natural logarithm (0.1 added to 0 HSCOREs and 0%+) and (2) square root. Our primary end point was MA.27 distant disease-free survival (DDFS) at a median 4.1-year follow-up, and secondary end point was event-free survival (EFS). Univariate survival with cut points at SDs about a mean of 0 (≤–1; (–1, 0]; (0, 1]; >1) was described with Kaplan-Meier plots and examined with Wilcoxon (Peto-Prentice) test statistic. Adjusted Cox multivariable regressions had two-sided Wald tests and nominal significance P < .05. RESULTS Of 7,576 women accrued, 3,048 women's tumors had machine-quantitated image analysis results: 2,900 (95%) for ER, 2,726 (89%) for PgR, and 2,582 (85% of 3,048) with both ER and PgR. Higher statistically standardized ER and PgR HSCORE and %+ were associated with better univariate DDFS and EFS ( P < .001). In multivariable assessments, ER HSCORE and %+ were not significantly associated ( P = .52-.88) with DDFS in models with PgR, whereas higher PgR HSCORE and %+ were significantly associated with better DDFS ( P = .001) in models with ER. CONCLUSION Adjunctive statistical standardization differentiated quantitated levels of ER and PgR. Patients with higher ER- and PgR-standardized units had superior DDFS compared with those with HSCOREs and %+ ≤–1.
Outcomes of Near‐Total and Subtotal Resection of Sporadic Vestibular Schwannoma: A Systematic Review and Meta‐Analysis
Kocharyan, Arminé , Daher, Ghazal S. , Curry, Steven D. , Klimara, Miles J. , Coleman, Sarah, Manzoor, Nauman F. , Carlson, Matthew L. , Farrokhian, Nathan , Oleson, Jacob

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 1, 2024 | Volume: 171 | Issue: 3 | Pages: 642-657

10.1002/ohn.823 | PMID 38822753 Get It

AbstractObjectiveTo evaluate tumor control and facial nerve outcomes after gross‐total (GTR), near‐total (NTR), and subtotal resection (STR) of sporadic vestibular schwannomas (VS).Data SourcesPubMed, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were searched in August 2021 through inception following PRISMA guidelines.Review MethodsEnglish language articles reporting tumor control and facial nerve outcomes of adults (≥18 years) with NTR and STR of VS were evaluated. Study characteristics, demographics data, tumor characteristics, type of surgical intervention, and outcome measures on tumor control and facial nerve function were collected. Pooled relative risk (RR) estimates for tumor recurrence and facial nerve outcomes were calculated and stratified by extent of resection.ResultsFrom an initial search of 2504 articles, 48 studies were included in the analysis. When comparing 1108 patients who underwent NTR to 3349 patients with GTR, the pooled RR of recurrence in the NTR cohort was 2.94 (95% confidence interval [CI] 1.65‐5.24, P = .0002). When comparing 1016 patients who underwent STR to 6171 patients with GTR, the pooled RR of recurrence in the STR cohort was 11.50 (95% CI 6.64‐19.92, P < .0001). Estimates for risk of tumor regrowth for less‐than‐complete resection are presented. There was no elevated risk of adverse facial nerve outcome (defined as House‐Brackmann grade III and above) in each category of extent of resection compared to GTR.ConclusionExtent of resection predicts risk of tumor recurrence/regrowth following microsurgical resection. Favorable facial nerve outcome should be weighed against the increased risk of regrowth and the potential need for further treatment.
Modeling and measurement of lead tip heating and resonant length for implanted, insulated wires
Speltz, Lydia J. Bardwell , Shu, Yunhong , Tarasek, Matthew , Trzasko, Joshua D. , Bernstein, Matt A. , Bardwell Speltz, Lydia J , Bernstein, Matt A , Lee, Seung‐Kyun , Foo, Thomas

Mayo Clinic

Magnetic Resonance in Medicine | May 31, 2024 | Volume: 92 | Issue: 4 | Pages: 1714-1727

10.1002/mrm.30145 | PMID 38818673 Get It

AbstractPurposeTo study implant lead tip heating because of the RF power deposition by developing mathematical models and comparing them with measurements acquired at 1.5 T and 3 T, especially to predict resonant length.Theory and MethodsA simple exponential model and an adapted transmission line model for the electric field transfer function were developed. A set of wavenumbers, including that calculated from insulated antenna theory (King wavenumber) and that of the embedding medium were considered. Experiments on insulated, capped wires of varying lengths were performed to determine maximum temperature rise under RF exposure. The results are compared with model predictions from analytical expressions derived under the assumption of a constant electric field, and with those numerically calculated from spatially varying, simulated electric fields from body coil transmission. Simple expressions for the resonant length bounded between one‐quarter and one‐half wavelength are developed based on the roots of transcendental equations.ResultsThe King wavenumber for both models more closely matched the experimental data with a maximum root mean square error of 9.81°C at 1.5 T and 5.71°C at 3 T compared to other wavenumbers with a maximum root mean square error of 27.52°C at 1.5 T and 22.01°C for 3 T. Resonant length was more accurately predicted compared to values solely based on the embedding medium.ConclusionAnalytical expressions were developed for implanted lead heating and resonant lengths under specific assumptions. The value of the wavenumber has a strong effect on the model predictions. Our work could be used to better manage implanted device lead tip heating.